2024
A SOCIAL corporate bond is issued, where the vast majority of the proceeds will be used for refinancing of the old bond issued in 2021.
OX124, a high-dose naloxone rescue medication for opioid overdoses, is filed with the FDA seeking US market approval.
2023
The first exploratory studies in large molecules, such as vaccine, are initiated with good results.
2022
Thanks to the versatile AmorphOX®-technology the pipeline is growing with among others OX640, a nasal epinephrine medication for allergic reactions. The first clinical study is conducted for OX640 which shows positive data when comparing to today´s standard treatment EpiPen®.
2021
In November Orexo announces its next generation drug delivery technology AmorphOX. This powder-based technology was developed to meet the high requirements for rapid absorption and excellent bioavailability in opioid overdose rescue medications. For APIs that are unstable, e.g. due to sensitivity to temperature changes or humidity, AmorphOX contributes to improved stability and shelf life.
2020
The digital portfolio continues to grow with a therapy for treatment of depression, Deprexis®, also developed by Orexo´s partner GAIA and with multiple clinical trials showing its efficacy. Orexo owns the US rights for Deprexis.
Zubsolv® US gross sales since start reached USD 1 billion.
2019
Orexo enters a partnership with GAIA AG, a world leader within digital therapeutics, with the aim to develop a digital therapy for treatment of opioid use disorder worldwide, MODIA®. The partnership enlarges when Orexo acquires the US rights for Vorvida®, a scientifically proven digital therapy for alcohol misuse including alcohol use disorder.
2018
The company wins a multiyear patent battle against the generic company Teva/Actavis securing patent protection for Zubsolv in the US until 2032. Shortly thereafter the company internalizes its sales force.
2017
Orexo joins the UN Global Compact, supporting their principles for a more sustainable world.
2016
After three years in the US, Orexo are selling Zubsolv for more than SEK 480 million and more than SEK 1 000 million gross in total, thereby reaching the first full year in history with profitability.
2015
Orexo divests its subsidiary Kibion, which also includes the product Diabact® UBT.
2013
Orexo establishes a commercial subsidiary in the US and launches Zubsolv, for treatment of opioid use disorder, in September 2013. The launch takes place just ten weeks after the FDA approval.
